High Need for a New Phosphate Binder Exists–Fewer Pills, Better Efficacy in Reducing Phosphorus and Improved Tolerability Rated as Higher Unmet Needs

August 6, 2014

Nephrologists Seem More Confident That an Iron-Based Phosphate Binder Will Impact the Use of IV Iron vs. the Use of ESAs, According to Findings from Decision Resources Group

BURLINGTON, Mass., Aug. 6, 2014 /PRNewswire/ — Decision Resources Group finds that there is a high need for new phosphate binders to treat hyperphosphatemia among surveyed U.S. nephrologists (n=102). Phosphate binders with fewer pills, better efficacy in reducing serum phosphorous and improved tolerability are rated as higher unmet needs to surveyed nephrologists than safety, limited drug interactions, availability in a variety of oral formulations and areas outside of phosphorous control (e.g. impact on hemoglobin, TSAT/ferritin and LDL, respectively).


Other key findings from the report entitled Special Report: The Impact of New Iron-Based Phosphate Binders on the Hyperphosphatemia Market (US) 2014:

    --  Aided Awareness: Not surprisingly, over 60 percent of nephrologists
        report aided awareness of Velphoro--significantly higher than 40 percent
        of nephrologists who report aided awareness of Zerenex, which has filed
        a new drug application to the U.S. FDA with PDUFA date of September 7,
    --  Perceptions of Velphoro and Zerenex Uniqueness: Just over one-half of
        surveyed nephrologists report that Velphoro and Zerenex are highly
        unique compared with currently available phosphate binders. The
        remaining physicians tend to report that the products are moderately
    --  Velphoro Non-Prescribers: Over 40 percent of non-prescribers expect to
        start prescribing Velphoro, which was FDA approved in November 2013, in
        the dialysis setting in the next three months.
    --  Impact of Iron-Based Binders on the use of IV iron and
        erythropoiesis-stimulating agents (ESAs): Surveyed nephrologists seem
        more confident that an iron-based phosphate binder will impact the use
        of IV iron vs. the use of ESAs, and they are more likely to believe that
        Zerenex vs. Velphoro will have an impact on the use of IV iron.
    --  Patient Case Studies: The report discusses four different patient case
        studies. In one study of a hypothetical patient with well-managed labs
        on a calcium-based phosphate binder, about the same percentage of
        surveyed nephrologists believe Zerenex and Velphoro are appropriate for
        this patient, respectively.
    --  Future Use of Velphoro: Six months from now, surveyed nephrologists
        expect greater than 10 percent of their hemodialysis patients to be on

Comments from Decision Resources Group Director Rob Dubman:

    --  "This report appears to indicate that there is a misperception about
        Velphoro and its possible benefits on improving iron parameters, as
        surveyed nephrologists rated Velphoro significantly high than Renvela on
        this attribute. As noted in the prescription information, trials
        indicate that Velphoro has no meaningful clinical impact in serum iron
        compared to the active control, but some physicians believe it does. The
        misperception may entice more use of Velphoro, or it may mean an
        opportunity for Zerenex to educate physicians correctly, in the event it
        receives FDA approval next month."

About Decision Resources Group

Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. Clients rely on this analysis and data to make informed decisions. Find out more at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or

registered trademarks of their respective holders.

For more information, contact:

Decision Resources Group

Christopher Comfort



Logo – http://photos.prnewswire.com/prnh/20130103/MM36768LOGO

SOURCE Decision Resources Group

Source: PR Newswire

comments powered by Disqus